Mucosis B.V.
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands
Trade Register / KvK: 02096219
In addition to the intranasal Mimopath™-based influenza vaccine, our scientists and collaborators have demonstrated in animal models that Mimopath-based vaccines also protect against live parasites (malaria) and bacteria (Streptococcus pneumonia, Yersinia pestis). Moreover, Mimopath™-based vaccines were shown to be effective both as an injectable and an intranasal vaccine. This forms the basis for a broad application of this new and innovative vaccine technology
31.05.10 Mucosis receives financial support from the Dutch government for its FluGEM program
more >
27.04.10 Mucosis appoints Dr. Roberto Grimandi as chief medical officer
more >
22.09.09 Mucosis receives key US patent covering its Mimopath™ technology
more >
28.01.09 Mucosis B.V. and PATH start development of pneumococcal vaccines
more >
15.12.08 Mucosis B.V. and TNO announce flu vaccine research and development partnership.
more >
10.12.07 News article in “Het Financieele Dagblad”.
more >
06.11.08 Mucosis B.V. appoints Dr. Govert Schouten as CEO. more >
10.09.07 Mucosis raises € 3 million in first financing round more >